ijms-logo

Journal Browser

Journal Browser

Special Issue "Molecular Mechanisms of Schizophrenia and Novel Targets"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: 30 June 2021.

Special Issue Editor

Prof. Juan F. Lopez-Gimenez
E-Mail Website
Guest Editor
CSIC—Instituto de Parasitologia y Biomedicina Lopez Neyra (IPBLN), Granada, Spain
Interests: schizophrenia; neurotransmitter receptors; cell signaling; genomics; proteomics; molecular pharmacology; antipsychotics.

Special Issue Information

Dear Colleagues,

The biological basis of schizophrenia, and many other mental diseases, has been the object of investigation for neuroscientists and psychiatrists over the last century. It is now well accepted that any scientific advance leading to the elucidation of the pathophysiology of these mental disorders, in particular schizophrenia and psychosis, will facilitate the comprehension of brain functioning in those aspects of mind and consciousness as well as the development of therapeutic strategies to treat these illnesses. During the last few decades, we have witnessed an extraordinary advance in all aspects of molecular approaches to interrogating mechanisms involved in biological processes, from the subcellular level to a more organized anatomical or physiological order. In this Special Issue, we aim to present a collection of the latest advances in the molecular basis of schizophrenia, covering a multidisciplinary perspective that includes molecular pharmacology, cellular signaling, genomics, and proteomics.

Prof. Juan F. Lopez-Gimenez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • schizophrenia
  • neurotransmitter receptors
  • cell signaling
  • genomics
  • proteomics
  • molecular pharmacology
  • antipsychotics
  • cellular models

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
Int. J. Mol. Sci. 2021, 22(8), 4119; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22084119 - 16 Apr 2021
Viewed by 391
Abstract
Schizophrenia is a complex psychopathology whose treatment is still challenging. Given the limitations of existing antipsychotics, there is urgent need for novel drugs with fewer side effects. SEP-363856 (SEP-856) is a novel psychotropic agent currently under phase III clinical investigation for schizophrenia treatment. [...] Read more.
Schizophrenia is a complex psychopathology whose treatment is still challenging. Given the limitations of existing antipsychotics, there is urgent need for novel drugs with fewer side effects. SEP-363856 (SEP-856) is a novel psychotropic agent currently under phase III clinical investigation for schizophrenia treatment. In this study, we investigated the ability of an acute oral SEP-856 administration to modulate the functional activity of specific brain regions at basal levels and under glutamatergic or dopaminergic-perturbed conditions in adult rats. We found that immediate-early genes (IEGs) expression was strongly upregulated in the prefrontal cortex and, to a less extent, in the ventral hippocampus, suggesting an activation of these regions. Furthermore, SEP-856 was effective in preventing the hyperactivity induced by an acute injection of phencyclidine (PCP), but not of d-amphetamine (AMPH). The compound effectively normalized the PCP-induced increase in IEGs expression in the PFC at all doses tested, whereas only the highest dose determined the major modulations on AMPH-induced changes. Lastly, SEP-856 acute administration corrected the cognitive deficits produced by subchronic PCP administration. Taken together, our data provide further insights on SEP-856, suggesting that modulation of the PFC may represent an important mechanism for the functional and behavioural activity of this novel compound. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Schizophrenia and Novel Targets)
Show Figures

Figure 1

Back to TopTop